Breast cancer survival in the US and Europe: A CONCORD high-resolution study

Autor: Karin Peignaux, Hans H. Storm, Milena Sant, Paolo Baili, Michel Velten, Michel P Coleman, Chakameh Safaei Diba, Sabine Siesling, Marc Colonna, Tiefu Shen, Ana Torrella-Ramos, Paolo Contiero, Rosemary D. Cress, Claudia Cirilli, Susan Bolick, Per-Uno Malmström, Adele Traina, Laufey Tryggvadottir, John P Fulton, Lisa C. Richardson, Maja Primic-Žakelj, María José Sánchez, M. Isabel Izarzugaza, Holly J. Wolf, Adri C. Voogd, Franco Berrino, Anne Sophie Woronoff, Hannah K. Weir, Timo Hakulinen, Jadwiga Rachtan, Tiiu Aareleid, Pascale Grosclaude, Maria J. Schymura, Claudia Allemani, Marina Vercelli, Magdalena Bielska-Lasota, Emanuele Crocetti, Eva Ardanaz, Xiao-Cheng Wu, Rosario Tumino
Přispěvatelé: Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, University of Twente [Netherlands], Department of Epidemiology and Biostatistics, National Institute for Health Development and Estonian Cancer Registry, Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública (CIBERESP), Los Centros de Investigación Biomédica en Red (CIBER), Navarra Public Health Institute, Leyre 15, Fondazione IRCCS Instituto Nazionale dei Tumori, Registre des cancers de l'Isère, registre des Cancers de l'Isère, Cancer Registry and Environmental Epidemiology Unit, Fondazione IRCCS, FRANCIM, Réseau des registres français du cancer, Department of Oncology, Clinical Sciences, Barngatan 2B, Lund University [Lund], Cracow Cancer Registry, M.Sklodowsk-Curie Memorial Cancer Institute, Granada Cancer Registry, Andalusian School of Public Health [Granada], Cancer Registry, Civile - M.P.Arezzo Hospital, Bas-Rhin Cancer Registry, EA 3430, Department of Epidemiology and Public Health, Faculty of Medicine, Paul Strauss Comprehensive Cancer Center, Liguria Cancer Registry, Descriptive Epidemiology Unit, National Cancer Research Institute, Recherche en Epidémiologie et Prévention, Tarn Cancer Registry, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Epidemiologie, RS: GROW - School for Oncology and Reproduction, Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública ( CIBERESP ), Andalusian School of Public Health, Azienda Ospedaliera 'Civile M.P.Arezzo', Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Zdroj: International Journal of Cancer
International Journal of Cancer, Wiley, 2013, 132 (5), pp.1170-1181. ⟨10.1002/ijc.27725⟩
International Journal of Cancer, 132(5), 1170-1181. Wiley
International Journal of Cancer, Wiley, 2013, 132 (5), pp.1170-1181. 〈10.1002/ijc.27725〉
ISSN: 0020-7136
1097-0215
Popis: International audience; Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.
Databáze: OpenAIRE
Externí odkaz: